SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp rally is drawing attention after Morgan Stanley named it a top pick, citing AWS growth and AI opportunities. Traders are broadly bullish, though some question whether the move can hold and point to earnings and technical resistance as potential tests.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgraded CoreWeave to Buy while lowering its price target, drawing attention after a sharp selloff in AI infrastructure stocks. Traders debated whether the upgrade and AI demand could support a rebound or whether heavy debt and financing concerns would keep pressure on the shares.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Better-than-expected third-quarter results and a substantially more upbeat 2027 earnings outlook are driving CLF attention and a sharp rally. Traders are debating whether the forecast and steel-price tailwinds can overcome debt and execution concerns, while some view the move as vulnerable to profit-taking or short-covering volatility.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are drawing attention after a sharp slide and technical breakdown, with traders repeatedly pointing to insider share sales as added selling pressure. Some view the sales as planned and the decline as disconnected from the companys growth, while others worry about management confidence and cite broader Southeast Asian market and oil-related risks.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine is surging after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, strengthening the companys path toward an FDA resubmission. Traders are broadly bullish and debating a possible short squeeze, while some cite dizziness concerns and potential profit-taking.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBios expanded FDA approval of ANKTIVA for papillary-only BCG-unresponsive bladder cancer, alongside long-term Phase 3 data showing durable responses and cystectomy avoidance, is driving attention. Traders are frustrated by the share-price drop despite the positive developments, debating a sell-the-news reaction and broader biotech weakness versus unverified claims of short-selling pressure.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

CBRS is drawing attention amid a steep post-IPO selloff, with traders pointing to successive insider-share unlocks and a broader AI and semiconductor pullback. Bears cite the companys high valuation, scaling concerns and OpenAI dependence, while bulls argue the decline is overdone and are buying dips.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

Traders are focused on AEP and X-energy evaluating a potential 960-MW small modular reactor project in Indiana, with Amazon funding development and potentially buying power long termfueling optimism about nuclear power for data centers. The project remains at the evaluation stage, and enthusiasm over the opportunity is tempered by concern about XEs sharp selloff and the long path to commercial deployment.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

Almontys investor-day webcast is driving concern, with traders criticizing CEO Lewis Blacks presentation and questioning whether it signaled an undisclosed problem. Others say the content sounded positive and see no clear negative update, leaving the selloffs cause uncertain.

Dynex Capital, Inc. is an internally managed mortgage real estate investment trust. It engages in the business of investing in mortgage-backed securities. The company was founded on December 18, 1987 and is headquartered in Glen Allen, VA.

Dynex Capital, Inc.

Dynexs Q3 results have focused attention on a sharp book-value decline as wider agency mortgage spreads drove losses, alongside earnings below the dividend payout. Traders are split between buying the dip on managements confidence in liquidity and future spread recovery, and worrying about dividend coverage and further share-price downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its third quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (SEC). The...

Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that Sebela Womens Health will present interim results from an ongoing Phase 3 study evaluating MIUDELLA, a hormone-free, copper intrauterine...

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Organon to Present New Real-World Analysis of VTAMA (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that a new real-world analysis of patients with atopic dermatitis (AD) treated with VTAMA (tapinarof) cream, 1% will be on display at the 2026 Fall...

Is Trending Stock Organon & Co. (OGN) a Buy Now?

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA, a Hormone-Free Intrauterine Device

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the US Food and Drug Administration (FDA) has accepted for review Sebela Womens Healths supplemental New Drug Application (sNDA) for MIUDELLA...

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know  

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Organon Opens REMS Program for MIUDELLA Ahead of Anticipated Commercial Availability

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the MIUDELLA (copper intrauterine system) Risk Evaluation and Mitigation Strategy (REMS) Program is now open for enrollment at...

Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Pharmaceutical giants are aggressively pursuing acquisitions to offset looming patent cliffs, as major blockbuster drugs face loss of exclusivity over the next several years.</li><li>Firms are trying to add new drugs to their portfolio with their deals, expanding into new or supplementing existing therapeutic areas.&nbsp;</li><li>Average deal size has climbed to $527.3 million in 2026, up from $365 million in 2025, CNBC reported.</li></ul>Global biopharma mergers and acquisitions have accelerated sharply in 2026, with deal value reportedly reaching $106 billion across 201 transactions through early June.If the current pace continues, the sector is projected to exceed $250 billion in total deal value for the full year—the strongest performance since the 2019 pre-pandemic peak, CNBC <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/06/04/biotech-ma-dealmaking-pharma-106-billion.html">reported</a>, citing PitchBook data.Pharmaceutical giants are aggressively pursuing acquisitions to offset looming patent expiries, as major blockbuster drugs face loss of exclusivity over the next several years. Firms are trying to add new drugs to their portfolio with their deals, expanding into new or supplementing existing therapeutic areas.“Pharma companies [are] really buying stuff like it’s going out of fashion,” Rajesh Kumar, head of life sciences and healthcare equity research at HSBC, told CNBC.Activity has shifted heavily toward strategic “bolt-on” acquisitions in the $1 billion to $5 billion range rather than large leveraged buyouts or mega-mergers, Nanna Lüneborg, general partner at life sciences venture capital firm Forbion, told CNBC. She doesn’t believe pharma is panic buying, but noted that many companies are prioritizing products that are close to commercialization while also investing in earlier-stage assets to gain access to innovative new technologies.Average deal size has climbed to $527.3 million so far in 2026, up from $365 million in 2025, CNBC reported.&nbsp;<h2 class="st-heading-2">Five Biggest Mergers And Acquisitions In US Biopharma Space In 2026</h2>Here are the five largest announced year-to-date:<ul><li>Sun Pharmaceutical Industries acquires Organon: India’s Sun Pharma <a href="https://stocktwits.com/news-articles/markets/equity/ogn-stock-jumps-after-sun-pharma-all-cash-buyout-offer/cZBNaqaRe2f">agreed</a> to buy New Jersey-based Organon in an all-cash deal at $14 per share for an $11.75 billion enterprise value. Organon’s portfolio of more than 70 medicines, including a strong biosimilars and women’s health franchise, gives Sun immediate scale in the U.S., China, and Brazil.</li><li>Gilead Sciences (<a href="https://stocktwits.com/symbol/GILD">GILD</a>) acquires Arcellx: The $7.8 billion deal, <a href="https://stocktwits.com/news-articles/markets/equity/why-did-aclx-stock-surge-in-pre-market-gilead-acquisition/cZRtFxoR4yT">announced</a> in the first quarter and completed on April 28, bolsters Gilead’s oncology and autoimmune pipeline with Arcellx’s next-generation CAR-T cell therapy for multiple myeloma.</li><li>Merck &amp; Co. (<a href="https://stocktwits.com/symbol/MRK">MRK</a>) acquires Terns Pharmaceuticals: Merck purchased the California-based biopharma for $6.7 billion in a deal <a href="https://stocktwits.com/news-articles/markets/equity/merck-to-acquire-terns-signaling-fresh-push-in-competitive-cancer-drug-race/cZ3YnhpRISB">announced</a> in late March. The acquisition centers on Terns' oral drug candidate TERN-701 for chronic myeloid leukemia.</li><li>Eli Lilly (<a href="https://stocktwits.com/symbol/LLY">LLY</a>) acquires Centessa Pharmaceuticals: The $7.8 billion total consideration <a href="https://stocktwits.com/news-articles/markets/equity/cnta-stock-surges-pre-market-what-s-the-eli-lilly-connection/cZEPMWsRIV7">deal</a>, announced in March, targeted Centessa’s pipeline of experimental therapies for the treatment of excessive daytime sleepiness and related neurological conditions.&nbsp;</li><li>Biogen (<a href="https://stocktwits.com/symbol/BIIB">BIIB</a>) acquires Apellis Pharmaceuticals: Biogen gained the Massachusetts-based company’s approved therapies Syfovre and Empaveli, plus additional immunology assets, in a $5.6 billion <a href="https://stocktwits.com/news-articles/markets/equity/apls-stock-soars-after-biogen-acquire-5-6b-deal/cZEPMW3RIVe">deal</a> announced on March 31.</li></ul>The State Street SPDR S&amp;P Biotech ETF (<a href="https://stocktwits.com/symbol/XBI">XBI</a>), which tracks the S&amp;P Biotechnology Select Industry Index, has risen 9% year-to-date, trading near $130.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/gm-stock-climbs-as-former-cruise-team-reportedly-returns-to-build-hands-free-consumer-vehicles/cZ0ZZ0PRez5">GM Stock Climbs As Former Cruise Team Reportedly Returns To Build Hands-Free Consumer Vehicles</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A photo illustration showing a mix of various tablets and pharmaceutical products, primarily manufactured by U.S. pharmaceutical companies, photographed in Edmonton, Alberta, Canada, on April 10, 2025 (Photo by Artur Widak/NurPhoto via Getty Images)

Biopharma M&A has surged to $106 billion across 201 deals through early June 2026, putting the sector on track for its strongest full-year total since the 2019 pre-pandemic peak, CNBC reported.

Arcellx Inc

Apellis Pharmaceuticals Inc

Biogen Inc

Centessa Pharmaceuticals PLC - ADR

Gilead Sciences, Inc.

Lilly(Eli) & Co

Merck & Co Inc

Terns Pharmaceuticals Inc

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$13.75
Prev Close	$13.76
Open	$13.78
Dividend Yield	4.74%
50-Day Moving Average	$13.72
Beta	0.82
Avg. Volume	2.61M
PE Ratio	17.63

52-Week High	$13.83
52-Week Low	$5.69
Market Capitalization	$3.61B
EPS (Annual)	$0.7171
Price to Book	3.59
Revenue Per Employee	$621,600.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

OGN Fundamentals